Home Sectors Healthcare Current Valuation: Enanta Pharmaceuticals (NASDAQ: ENTA)

Current Valuation: Enanta Pharmaceuticals (NASDAQ: ENTA)


Enanta Pharmaceuticals is in the healthcare sector and trades as part of the biotechnology industry. The company CEO is Jay R. Luly. Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Group uses its chemistry-driven approach and drug discovery capabilities to develop its products.

Previous Intraday Trading Performance:

The ENTA stock showed a previous change of -1.60% with an open at 103.65 and a close of 101.37. It reached an intraday high of 103.65 and a low of 100.71.

SeekingAlpha:  Conatus up 22% ahead of Emricasan data presentation


The stock has a market cap of $2.0b with 19.4m shares outstanding, of which the float is 18.3m shares. Trading volume reached 165,946 shares compared to its average volume of 280,347 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Enanta Pharmaceuticals shares returned 3.56% and in the past 30 trading days it returned 28.28%. Over three months, it changed 36.93%. In one year it has changed 17.58% and within that year its 52-week high was 127.77 and its 52-week low was 64.09. ENTA stock is 58.18% above its 52 Week Low.

Our calculations show a 200 day moving average of 91.10 and a 50 day moving average of 87.32. Currently ENTA stock is trading 11.27% above its 200 day moving average.

SeekingAlpha:  Conatus up 22% ahead of Emricasan data presentation


The last annual fiscal EPS for the company was reported at 3.48 that ended on 30th of September 2018, which according to the previous close, that is a PE of 29.13. Based on 4 analyst estimates, the consensus EPS for the next quarter is 1.24. The TTM EPS is 3.66, which comes to a TTM PE of 27.70.

The following are the last four quarter reported earnings per share:
12-31-2018:  1.25
09-30-2018:  1.30
06-30-2018:  0.97
03-31-2018:  0.61

Indicators to Watch:

Based on the latest filings, there is 126.40% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.40

SeekingAlpha:  Ametek Is A Market Leader But Looks Overvalued

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 23.61%, return on assets is 22.11%, profit margin is 36.38%, price-to-sales is 8.40 and price-to-book is 4.69.

Company Scores:

All scores are out of six:
 0  :Valuation Score
 5  :Past Performance Score
 5  :Financial Strength Score
 0  :Future Growth Score
 0  :Dividend Score
 2  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.